#VisualAbstract: Post-induction chemotherapy Epstein-Barr virus DNA is an effective prognostic indicator for nasopharyngeal carcinomas
Click to read the study in the European Journal of Cancer.
Tag: nasopharyngeal carcinoma
#VisualAbstract: Camrelizumab plus gemcitabine and cisplatin improves progression-free survival in patients with recurrent or metastatic nasopharyngeal carcinoma
Click to read the study in The Lancet Oncology.
Adjuvant metronomic capecitabine improves survival in patients with locoregionally advanced nasopharyngeal carcinoma
1. Adjuvant capecitabine resulted in fewer instances of disease recurrence and death compared to standard therapy. 2. Overall and failure-free ...
#VisualAbstract: Pembrolizumab plus cetuximab shows early clinical efficacy for patients with recurrent or metastatic head and neck squamous cell carcinoma
Click to read the study in The Lancet Oncology.
Proton therapy associated with reduced toxicity and equivalent survival outcomes vs radiation therapy amongst patients with nonmetastatic nasopharygneal carcinoma
1. Intensity-modulated proton therapy was associated with fewer adverse events than intensity-modulated radiation therapy in the treatment of patients with ...
#VisualAbstract: Plasma Epstein-Barr virus DNA may have prognostic value for patients with nasopharyngeal carcinoma
Click to read the study in Clinical Cancer Research.
#VisualAbstract: Docetaxel, cisplatin, and cetuximab regimen is a safe alternative for patients with squamous cell carcinoma of the head and neck
Click to read the study in The Lancet Oncology.
#VisualAbstract: Hyperfractionated radiotherapy with concomitant chemotherapy is highly effective for locally advanced head and neck cancers
Click to read the study in The Lancet Oncology.
#VisualAbstract: Lobaplatin-based induction chemotherapy is safe and efficacious for patients with advanced nasopharyngeal carcinomas
Click to read the study in The Lancet Oncology.
#VisualAbstract: Endoscopic surgery improves survival compared to radiotherapy in patients with locally recurrent nasopharyngeal carcinoma
Click to read the study in Lancet Oncology.
